The Second International Workshop on Multiple Endocrine Neoplasia Type 2 Syndromes
B. A. J. Ponder
C. E. Jackson

Impact of Prospective Screening for Multiple Endocrine Neoplasia Type 2
R. F. Gagel
A. H. Tashjian, Jr
T. Cummings
N. Papathanasopoulos
S. Reichlin

Screening in Medullary Thyroid Carcinoma
C. Calmettes

MEN-2 Syndrome: The Value of Screening and Central Registration; A Study of Six Kindreds in The Netherlands
H. F. A. Vasen
A. C. Nieuwenhuijzen Kruiseman
A. M. J. Meers
C. J. M. Lips
E. K. M. Beekers
W. M. Wieringa
R. A. Geerdink

Characteristics of a Family with the MEN-2 Syndrome
H. R. Haak
A. C. Nieuwenhuijzen Kruiseman

Multiple Endocrine Neoplasia Type 2A: A Northern Ireland and Australian Family
D. R. Hadden
F. O'Reilly
L. Kennedy
C. Russell

Screening for Early Asymptomatic Pheochromocytoma in MEN-2
M. Telienias-Berg
B. Berg
B. Hamberger
S. Tibblin

Calcitonin Gene-Related Peptide and Calcitonin in MEN-2 and Sporadic Pheochromocytomas: An Immunohistochemical Study
L. Johanssen
H. Daa Schrøder
S. Schifer

Calcitonin Gene Peptides: The Diagnostic Value of Measurement in Medullary Thyroid Carcinoma
S. I. Girgis
C. Lynch
J. C. Hillyard
J. C. Stevenson
P. A. Hill
D. W. R. MacDonald
I. MacIntyre

Clinical Value of Calcitonin and Carcinoembryonic Antigen Doubling Times in Medullary Thyroid Carcinoma
C. E. Jackson
R. A. Norum
G. B. Talpos
C. S. Feldkamp
A. H. Tashjian, Jr

Importance of Ultrasound Examination for the Follow-up of Medullary Thyroid Carcinoma: Comparison with Other Localization Methods
K. Prank
F. Raue
D. Lorenz
C. Herdärth
R. Ziegler

Radionuclide Imaging in Medullary Thyroid Carcinoma: Evaluation of Two New Radiopharmaceuticals
S. E. M. Clarke
C. R. Lazarus
M. N. Maitrey

Subtotal Adrenalectomy in Multiple Endocrine Neoplasia Type 2
B. Hamberger
M. Telienias-Berg
B. Cedermark
G. Grondal
B. Hansson
S. Werner

A Two-Site Immunoradiometric Assay for Serum Calcitonin Using Monoclonal Anti-Peptide Antibodies
P. Motte
M. Aït-Abdellah
P. Vazquez
P. Gardet
C. Bohuon
D. Bellot

Thyroid C-Cell Hyperplasia and Micronodules in Close Relatives of MEN-2A Patients: Pitfalls in Early Diagnosis and Reevaluation of Criteria for Surgery
C. J. M. Lips
I. R. Leo
M. J. H. Berends
W. H. Minder
P. P. Roeland Blok
R. A. Geerdink
W. H. L. Hackeng
J. M. M. Roelofs
H. F. A. Vasen
J. K. Vette
The Henry Ford Hospital Medical Journal is published quarterly by Henry Ford Hospital and is distributed to Henry Ford Hospital staff, alumni, and to medical centers, libraries, and physicians in the United States and abroad. It is also sent, upon request, to medical students in their third and fourth years of medical school. Medical students should state the year of their graduation when requesting the Journal. Requests should be sent to the Medical Journal Office, 411/413 New Center Pavilion, Henry Ford Hospital, 2921 W Grand Blvd, Detroit, MI 48202.

For changes of address, please enclose the old address label, give the complete new address, and allow six weeks for processing.

The Journal publishes the work of any current staff member or resident of Henry Ford Hospital, alumni, and participants in academic and scientific activities, meetings, and symposia sponsored by Henry Ford Hospital. The Journal is listed by Index Medicus and is intended to be a broad scientific forum for all areas of interest: clinical, research, technical, administrative, medical ethics, and patient care delivery. Complete instructions for authors wishing to submit a manuscript are printed at the back of the first issue of each year.

Back copies of the Journal are available from University Microfilms, 300 N Zeeb Rd, Ann Arbor, MI 48106, as 3.5 mm microfilms (Vols 1-20) or as 16 mm films (Vols 19-present).

EDITORIAL BOARD
Raymond C. Mellinger, MD
Editor
Brack A. Bivins, MD
Stanton B. Elias, MD
Michael Kleerekoper, MD
Conrad Lam, MD
Nathan W. Levin, MD
Richard M. Nowak, MD
Dennis R. Ownby, MD
Jeanne M. Riddle, PhD
Paul D. Stein, MD
Sarah Whitehouse, MAW
Managing Editor
Susan E. MacPhee, BA
Editorial Assistant
Robert H. Mohr, BA
Medical Art Director
Connie D. Cryar, BA
Editorial Consultant
Linda S. Taylor, BA
ex officio

© HENRY FORD HOSPITAL 1987
2799 West Grand Boulevard
Detroit, MI 48202
1-800-482-2404 (within Michigan)
1-800-521-7946 (outside Michigan)
Vol 35, Nos 2 & 3, 1987
ISSN 0018-0416
## Contents

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Second International Workshop on Multiple Endocrine Neoplasia Type 2 Syndromes</td>
<td>93</td>
</tr>
</tbody>
</table>
| *Bruce A.J. Ponder*  
*Charles E. Jackson* |      |
| Impact of Prospective Screening for Multiple Endocrine Neoplasia Type 2 | 94   |
| *Robert F. Gagel*  
*Armen H. Tashjian, Jr*  
*Tim Cummings*  
*Nick Papathanasopoulos*  
*Seymour Rechlin* |      |
| Screening in Medullary Thyroid Carcinoma | 99   |
| *C. Calmettes* |      |
| MEN-2 Syndrome: The Value of Screening and Central Registration; A Study of Six Kindreds in The Netherlands | 101  |
| *H.F.A. Vasen*  
*A.C. Nieuwenhuijzen Kruseman*  
*A.M.J. Moers*  
*C.J.M. Lips*  
*E.K.M. Beukers*  
*W.M. Wiersinga*  
*R.A. Geerdink* |      |
| Characteristics of a Family with the MEN-2 Syndrome | 104  |
| *Harm R. Haak*  
*Arie C. Nieuwenhuijzen Kruseman* |      |
| Multiple Endocrine Neoplasia Type 2A: A Northern Ireland and Australian Family | 107  |
| *David R. Hadden*  
*Fergus O'Reilly*  
*Laurence Kennedy*  
*Colin Russell* |      |
| Screening for Early Asymptomatic Pheochromocytoma in MEN-2 | 110  |
| *Margareta Telenius-Berg*  
*Bertil Berg*  
*Bertil Hamberger*  
*Sten Tibblin* |      |
| Calcitonin Gene-Related Peptide and Calcitonin in MEN-2 and Sporadic Pheochromocytomas: An Immunohistochemical Study | 115  |
| *Lis Johannsen*  
*Henrik Daa Schroder*  
*Soren Schifter* |      |
| Calcitonin Gene Peptides: The Diagnostic Value of Measurement in Medullary Thyroid Carcinoma | 118  |
| *Samia I. Girgis*  
*Catherine Lynch*  
*Carmel J. Hillyard*  
*John C. Stevenson*  
*Patricia A. Hill*  
*David W.R. MacDonald*  
*Iain MacIntyre* |      |
| Clinical Value of Calcitonin and Carcinoembryonic Antigen Doubling Times in Medullary Thyroid Carcinoma | 120  |
| *Charles E. Jackson*  
*Robert A. Norum*  
*Gary B. Talpos*  
*Carolyn S. Feldkamp*  
*Armen H. Tashjian, Jr* |      |
| Importance of Ultrasound Examination for the Follow-up of Medullary Thyroid Carcinoma: Comparison with Other Localization Methods | 122  |
| *Karin Frank*  
*Friedhelm Raue*  
*Dorothea Lorenz*  
*Christian Herfarth*  
*Reinhard Ziegler* |      |
| Radionuclide Imaging in Medullary Thyroid Carcinoma: Evaluation of Two New Radiopharmaceuticals | 124  |
| *S.E.M. Clarke*  
*C.R. Lazarus*  
*M.N. Maisey* |      |
| Subtotal Adrenalectomy in Multiple Endocrine Neoplasia Type 2 | 127  |
| *Bertil Hamberger*  
*Margareta Telenius-Berg*  
*Bjorn Cedermark*  
*Staffan Grondal*  
*Bengt-Goran Hansson*  
*Sigbritt Werner* |      |
| A Two-Site Immunoradiometric Assay for Serum Calcitonin Using Monoclonal Anti-Peptide Antibodies | 129  |
| *Philippe Motte*  
*Malika Ait-Abdellah*  
*Pascal Vauzelle*  
*Paule Gardet*  
*Claude Bohuon*  
*Dominique Bellet* |      |
| Thyroid C-Cell Hyperplasia and Micronodules in Close Relatives of MEN-2A Patients: Pitfalls in Early Diagnosis and Reevaluation of Criteria for Surgery | 133  |
| *Cees J.M. Lips*  
*John R. Leo*  
*Marianne J.H. Berends*  
*Werner H. Minder*  
*A.P. Roeland Blok*  
*Rolf A. Geerdink*  
*Wil H.L. Hackeng*  
*Jan M.M. Roelofs*  
*Hans F.A. Vasen*  
*Jan K. Vette* |      |
Immunohistochemistry in Medullary Thyroid Carcinoma: Prognosis and Distinction Between Hereditary and Sporadic Tumors 139
B. Franc
B. Caillou
A.M. Carrier
N. Dutriex-Berger
J. Floquet
M. Houcke
E. Justrabo
F. Lange
A. Pages
C. Rigaud
A. Schwartz
M. Viennet
M.F. Lebodic

In Vitro Secretion of Peptides of the Calcitonin Family: Calcitonin, Katacalcin, and Calcitonin Gene-Related Peptide 143
Friedhelm Raue
Hubert Serve
Eckard Rix
Reinhard Ziegler

Plasma and Tumor Levels of Somatostatin (SRIF) and Somatostatin Immunohistochemistry in Medullary Thyroid Carcinoma: Apparently Discrepant Preliminary Results 147
B. Franc
J.A. Chayvialle
E. Modigliani
C. Calmettes
B. Caillou
N. Dutriex-Berger
C. Houdent
M. Kujas

Different Mechanisms of Calcitonin, Calcitonin Gene-Related Peptide, and Somatostatin Regulation by Glucocorticoids in a Cell Culture of Human Medullary Thyroid Carcinoma 149
Gilbert J. Cote
Robert F. Gagel

Localization of a Radiolabeled Monoclonal Antibody to Calcitonin in Rat Medullary Thyroid Carcinoma Allografts 153
Naguib A. Samaan
Kuo-Pao Yang

Studies of Multiple Endocrine Neoplasia Type 2A Syndrome: Linkage Analyses and Comparison of Constitutional and Tumor Genotypes 157
Hideo Tateishi
Shin-ichiro Takai
Isamu Nishisho
Tetsuro Miki
Kazuyoshi Motomura
Makoto Okazaki
Akira Miyachi
Tatsuro Ikeuchi
Kohtaro Yamamoto
Tatsuo Hattori
Yuichi Kumahara
Hideo Matsumoto
Tasuku Honjo
Takesada Mori

Application of Minisatellite DNA Probes to Linkage in MEN-2 161
Bruce A.J. Ponder
Alec J. Jeffreys
Nicola E. Hartley
Clare Carter
Douglas F. Easton
Hakan Telenius
Margareta Telenius-Berg

One Large Kindred Excludes a Locus for Multiple Endocrine Neoplasia Type 2A From About 25% of the Human Autosomal Genetic Map 164
Andrew J. Pukstis
Judith R. Kidd
Carmela M. Castiglione
Beth A. Fletcher
Patricia D. Murphy
Lindsay A. Farrer
Myron Genel
Kenneth K. Kidd

Where is the Locus for Multiple Endocrine Neoplasia Type 2A? 168
Nancy E. Simpson
Kenneth K. Kidd

Contributing Authors 172

Henry Ford Hospital Medical Journal, established in 1953, is published quarterly as the official scientific publication of Henry Ford Hospital. Reproduction in whole or part without permission, except photocopies for noncommercial scientific or educational purposes only, is prohibited. All editorial correspondence should be directed to the Managing Editor. Subscription requests and changes of address should be sent to Henry Ford Hospital Medical Journal, 2921 W Grand Blvd, Detroit, MI 48202.

Henry Ford Hospital Medical Journal is included in Index Medicus and the Medline System. ISSN 0018-0416.
Glossary

As an outcome of these workshops, this glossary is provided to attempt to establish some uniformity of nomenclature. We call attention to the use of the Arabic numeral in MEN-2 rather than the potentially cumbersome Roman numerals. (Can you imagine MEN-XXXVIII?)

**MEN-2**: The multiple endocrine neoplasia type 2 syndrome (replaces the MEA term used previously to designate multiple endocrine adenomatosis; the term “neoplasia” covers the malignant lesions of these syndromes not covered by the “adenomatosis” term).

**MTC**: Medullary thyroid cancer or carcinoma used in this issue for consistency rather than MCT which is sometimes used referring to medullary carcinoma of the thyroid.

**MEN-2A**: The multiple endocrine neoplasia type 2 syndrome without the mucosal neuroma phenotype.

**MEN-2B**: The multiple endocrine neoplasia type 2 syndrome with the mucosal neuroma phenotype (sometimes referred to as MEN-3).

**MEN2A**: The designation for the mutant gene causing MEN-2A. (Used especially in reports of genetic linkage studies.)